Home
Molecular Diagnostics
4 June - 5 June 2008
Molecular Diagnostics

Personalised medicine is moving from science fiction to reality.

In Vitro Diagnostics currently represent an expanding market of around $30 billon – with Molecular Diagnostics represent a growing fraction of this market. Drugs developed with pharmacogenetic companion diagnostics hold a phenomenal potential to optimise treatments for patients and make enourmous profits for those who commercialise them.

As increasing understanding of genomics allows medical interventions to be tailored to the patient, SAE Media Group’s Molecular Diagnostics Conference will provide the perfect opportunity to keep abreast of developments. Both diagnostics companies and drug producers will benefit from hearing the latest thinking on diagnostic testing and pharmacogenetics.

With a panel of top industry experts, the conference will address a number of key areas including:

  • Developing companion diagnostics
  • Discovering and validating molecular biomarkers
  • Improving drug efficacy with personalised medicine
  • Using pharmacogenomics to increase drug safety
  • Market prospects and the health economics of diagnostics and personalised medicine
  • The regulatory regime for diagnostic tests

Confirmed speakers:

  • Eddie Blair, Managing Director, Integrated Medicines
  • Anil Modak, Associate Director, Medical Products Research and Development, Cambridge Isotope Laboratories
  • Glenn Miller, Vice President, General Manager, Genzyme
  • Ansar Jawaid, Statistical Genetics Group Leader, R&D Genetics, AstraZeneca
  • Daren Thorborn, HIV Project Leader, GlaxoSAE Media GroupthKline
  • David Johnston, Vice President and Chief Scientific Officer, Esoterix Clinical Trials Services
  • Angus Hastie, CEO, Human Genetic Signatures
  • David Huckle, Chief Executive, Adams Business Associates
  • Steven Wong, Professor of Pathology & Scientific Director, toxicology Department, Milwaukee County Examiners Office, Medical University of Wisconsin
  • Professor K.K. Jain, CEO, Jain PharmaBiotech
  • Eric Claas, Associate Professor, Department of Medical Microbiology, Leiden University Medical Centre
  • Fiona Rahman, Programme Manager - Clinical Diagnostics Healthcare EIA, Frost & Sullivan
  • Sian Astley, European Communications Manager, Norwich Bioscience Institutes & NuGO
  • Muireann Cohen, Research Associate, Imperial College London
  • Jorge Leon, CEO, Leomics Consulting

Conference agenda

clock

8:30

Registration & Coffee

clock

9:00

Chairman's Opening Remarks

David Huckle

David Huckle, Chief Executive, Adams Business Associates

clock

9:10

MOLECULAR DIAGNOSTICS - RESEARCH DEVELOPMENTS INTO CLINICAL PRACTICE

David Huckle

David Huckle, Chief Executive, Adams Business Associates

  • Application of Molecular Diagnostics in Life Science Research
  • Evolution of Uses for Pharmaceutical development
  • Evolution of Uses for Clinical Diagnostics
  • Evolution of Uses for Genetic Analysis
  • Market Quantification Comparisons for Molecular Diagnostics in Research, Drug Development and Clinical Diagnostics
  • clock

    9:50

    SAFETY AND EFFICACY BIOMARKERS - DRIVERS TO PERSONALISED HEALTHCARE

    Ansar Jawaid

    Ansar Jawaid, Statistical Genetics Group Leader, R&D Genetics, AstraZeneca

  • Challenges and opportunities of Personalised Healthcare
  • Experience with safety biomarkers
  • Experience with efficacy biomarkers
  • clock

    10:30

    Morning Coffee

    clock

    11:00

    ONE SIZE FITS ONE – A PERSONALISED APPROACH TO HIV

    Daren Thorborn

    Daren Thorborn, HIV Project Leader, GlaxoSmithKline R&D

  • Observations and associations
  • Using screening technologies to reduce serious drug toxicities in the clinic
  • clock

    11:40

    COMMERCIALISATION OF A PHARMACOGENETIC COMPANION DIAGNOSTIC FOR AN ANTIRETROVIRAL

    Hawazin Faruki

    Hawazin Faruki, Vice President, LabCorp

  • Market research on pgx readiness
  • Evidence-based decisions on test utilization
  • Technical and regulatory factors
  • clock

    12:20

    Networking Lunch

    clock

    13:50

    MARKET PROSPECTS FOR COMPANION DIAGNOSTICS AND PERSONALISED MEDICINE

    Dr. Fiona Rahman

    Dr. Fiona Rahman, Programme Leader - Clinical Diagnostics, Frost & Sullivan

  • Pharmacogenetics can give drugs that would have failed to gain approval another chance
  • But is explicitly limiting a drug’s potential market by personalisation ever really a good commercial idea?
  • Will personalised medicine mean the end of the era of ‘blockbusters’?
  • Strategies to achieve business success with companion diagnostics
  • Pricing and reimbursement opportunities for diagnostic tests and companion drugs
  • clock

    14:30

    MARKET OPPORTUNITIES IN NUTRIGENOMICS AND NUTRIGENETICS

    Siân Astley

    Siân Astley, European Communications Manager , Norwich BioScience Institutes (IFR & JIC) & NuGO

  • The latest work on genetic predispositions for obesity and heart disease
  • Developing diagnostic tests to aid prescribing nutraceuticals
  • The market for nutrigenomics
  • clock

    15:10

    Afternoon Tea

    clock

    16:20

    THE USE OF PHARMACOGENETIC MARKERS FOR PERSONALISED JUSTICE

    Steven How Yan Wong

    Steven How Yan Wong, Professor of Pathology & Scientific Director, toxicology Department, Milwaukee County Examiners Office, Medical College of Wisconsin

  • PGx in understanding the possible contribution of genetics to side effect of drugs in Driving-under-the influence of drug cases in court in the future
  • clock

    17:40

    Chairman’s Closing Remarks and Close of Day One

    clock

    8:30

    Registration & Coffee

    clock

    9:00

    Chairman's Opening Remarks

    Angus Hastie

    Angus Hastie, CEO, Human Genetic Signatures

    clock

    9:10

    A CONTINUUM OF CANCER CARE. MAKING Dx/Rx TRANSPARENT TO THE PATIENT

    Glenn Miller

    Glenn Miller, Vice President, General Manager, Genzyme Transgenics Corporation

  • Better disease characterization leads to better clinical decision making
  • Therapeutic selection, the role of the clinical laboratory
  • Therapeutic monitoring, moving beyond the subjective
  • Models of care that work for the patient
  • clock

    9:50

    MOLECULAR DIAGNOSTICS IN CLINICAL PRACTICE

    Eric Claas

    Eric Claas, Head of Molecular Diagnostics, Leiden Univ Medical Center

  • Replacing conventional diagnostic methods in routine microbiology
  • Improved diagnosis of infections by multiplexed molecular assays
  • When molecular test really make a difference for the patient
  • Reimbursement issues
  • Future development: where does it end
  • clock

    10:30

    Morning Coffee

    clock

    11:00

    THE BIG MARKETS: MOLECULAR DIAGNOSTICS FOR MICROBIAL PATHOGENS

    Angus Hastie

    Angus Hastie, CEO, Human Genetic Signatures

  • Market Dynamics: Current Mol Dx Infectious Disease Detection Approaches
  • New Target Technology for a Platform-Agnostic, Single-Plex,Pan-Species Screen
  • Routine Practicalities: Demonstrating Clinical Performance and Instrument Readiness
  • The IP Minefield: Sticking to a Proprietary Path
  • Business Applications: Licensing, Assay Direct and Platform Strategies
  • clock

    11:40

    THE PERSPECTIVE OF THE NHS

    Rob Elles

    Rob Elles, Chairman, National Genetics Reference Lab, Manchester

  • Personalised medicine and reducing adverse drug reactions
  • Cost-benefit judgements made by the NHS
  • Recent NICE decisions on approval of companion diagnostics e.g. Herceptin
  • The guidelines for implementing molecular diagnostics into clinical practice
  • clock

    12:20

    Networking Lunch

    clock

    13:50

    THE ROLE OF METABOLIC PROFILING IN BIOMEDICAL SCIENCES

    Muireann Coen

    Muireann Coen, Research Associate, Imperial College London

  • Analytical tools for metabolic profiling
  • Mathematical solutions for extracting biomarkers
  • Applications in animal models
  • Translation into man
  • Future perspevtives
  • clock

    14:30

    DIAGNOSTIC BREATH TEST IN PERSONALISED MEDICINE

    Anil Modak

    Anil Modak, Associate Director, Medical Products Research & Development, Cambridge Isotope Laboratories

  • Uracil-13C breath test to identify DPD/DPHD deficiency to personalize 5-FU therapy
  • Pantoprazole-13C breath test to identify CYP2C19 enzyme deficiency to personalize Helicobacter pylori eradication therapy
  • Dextromethorphan-13C breath test for evaluating CYP2D6 enzyme activity to personalize Tamoxifen therapy
  • Phenylalanine-13C breath test for monitoring liver regeneration in living human liver donor following transplant surgery
  • Sodium bicarbonate-13C breath test to monitor COPD patients suffering from hypercapnia
  • L-DOPA-13C breath test to personalize Parkinsons disease medication.
  • clock

    15:10

    Afternoon Tea

    clock

    15:40

    THE MOLECULAR DIAGNOSTICS MARKET IN THE US

    Jorge Leon

    Jorge Leon, CEO, Leomics Consulting

  • Forecast of future diagnostics markets
  • Technological, economical and cultural barriers in the US
  • clock

    16:20

    ECONOMIC VALUE OF COMPANION DIAGNOSTICS FROM A PARTNERING PERSPECTIVE

    Eddie Blair

    Eddie Blair, Director, Integrated Medicines Ltd

  • Context of value modeling and assumptions used
  • Cash flows from modeling and extension to market value
  • Effects of risk adjustment and macroeconomic considerations
  • Case studies where such value modeling has credibility
  • clock

    17:00

    Chairman’s Closing Remarks and Close of Conference

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download

    Title


    Description

    Download

    Title


    Description


    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SAE Media Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@saemediagroup.com

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    Group Booking

    Please complete the below form and a member of SAE Media Group’s booking team will be in contact within 24 hours

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SAE Media Group

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SAE Media Group , Ground Floor, India House, 45 Curlew Street, London, SE1 2ND, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smgconferences.com Email: events@saemediagroup.com
    Registered in England - SMi Group Ltd trading as SAE Media Group




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SAE Media Group.
    Full details of our privacy policy can be found here https://www.smgconferences.com/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data.privacy@smgconferences.com.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smgconferences.com/opt-out

    Fill in your details to download the brochure

    By submitting this form you agree to our privacy policy and consent to receiving communications, you may opt out at any time.